用经外部验证的群体药代动力学模型为重症成人患者持续输注哌拉西林提供给药建议
该研究用30例接受哌拉西林持续输注的重症成人患者(35份样本)数据,对6个已发表的群体药代动力学模型进行外部验证,采用预测法(偏差与不精密度)和模拟法评估。偏差与不精密度范围分别为-35.7%至295%和22.7%至295%。Klastrup等和Udy等的模型符合预设标准,被用于给药模拟;模拟显示,对肌酐清除率76 mL/min的中位患者,需负荷剂量4 g后维持剂量16 g/24 h持续输注,才能使90%患者血药浓度高于以最低抑菌浓度16 mg/L设定的药代动力学-药效学目标。作者据此制定了可供重症监护病房临床医生使用的哌拉西林持续输注给药列线图。
要点
- 外部验证数据集为30例重症成人患者、35份样本,均接受哌拉西林持续输注。
- 6个模型的偏差范围为-35.7%至295%,不精密度范围为22.7%至295%。
- 仅Klastrup等和Udy等的模型符合预设可接受标准,被用于后续给药模拟。
- 模拟显示,对肌酐清除率76 mL/min的中位患者,负荷剂量4 g后16 g/24 h持续输注可使90%患者高于最低抑菌浓度16 mg/L的目标。
- 作者据此制定了哌拉西林持续输注给药列线图,供重症监护病房临床医生使用。
适用人群与场景
- 接受哌拉西林持续输注的重症成人患者(外部验证数据集30例,35份样本)
诊断标准与关键阈值
- 药代动力学-药效学目标设定为最低抑菌浓度16 mg/L,要求90%患者血药浓度高于该目标。
处置流程与药物剂量
- 对肌酐清除率76 mL/min的中位患者,模拟显示需负荷剂量4 g后维持剂量16 g/24 h持续输注,方可使90%患者高于最低抑菌浓度16 mg/L的药代动力学-药效学目标。
研究设计与关键结果
- 研究类型为对已发表群体药代动力学模型的外部验证研究,使用30例重症成人患者(35份样本)接受哌拉西林持续输注的数据评估6个模型。
- 预测法评估显示,6个模型的偏差范围为-35.7%至295%,不精密度范围为22.7%至295%。
- Klastrup等和Udy等的模型符合预设可接受标准,被用于给药模拟评估目标达成概率。
- 模拟显示,对肌酐清除率76 mL/min的中位患者,负荷剂量4 g后16 g/24 h持续输注可使90%患者高于最低抑菌浓度16 mg/L的目标。
证据类型、等级与局限
- 证据类型:群体药代动力学模型的外部验证研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者制定了哌拉西林持续输注给药列线图,可供重症监护病房临床医生使用。
- 对肌酐清除率76 mL/min的重症成人患者,模拟提示负荷剂量4 g后16 g/24 h持续输注可达到最低抑菌浓度16 mg/L的目标(90%患者)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: BACKGROUND AND OBJECTIVE: Piperacillin is a broad-spectrum β-lactam antibiotic commonly prescribed in intensive care units. Many piperacillin population pharmacokinetic models have been published, but few underwent an external evaluation. External evaluation is an important process to determine a model's capability of being generalized to other hospitals. We aimed to assess the predictive performance of these models with an external validation dataset.
METHODS: Six models were evaluated with a dataset consisting of 30 critically ill patients (35 samples) receiving piperacillin by continuous infusion. Models were subject to prediction-based (bias and imprecision) and simulation-based evaluations. When a model had an acceptable evaluation, it was used for dosing simulations to evaluate the probability of target attainment.
RESULTS: Bias and imprecision ranged from - 35.7 to 295% and from 22.7 to 295%, respectively. The models of Klastrup et al. and of Udy et al. were acceptable according to our criteria and were used for dosing simulations. Simulations showed that a loading dose of 4 g followed by a maintenance dose of 16 g/24 h of piperacillin infused continuously was necessary to remain above a pharmacokinetic-pharmacodynamic target set as a minimal inhibitory concentration of 16 mg/L in 90% of patients, for a median patient with a creatinine clearance of 76 mL/min.
CONCLUSIONS: Despite the considerable variation in the predictive performance of the models with the external validation dataset, this study was able to validate two of these models and led to the elaboration of a dosing nomogram for piperacillin by continuous infusion that can be used by clinicians in intensive care units.
参考来源
- El-Haffaf I, Guilhaumou R, Velly L, et al. Using a Validated Population Pharmacokinetic Model for Dosing Recommendations of Continuous Infusion Piperacillin for Critically Ill Adult Patients. Clin Pharmacokinet. 2022. PMID: 35344155. doi:10.1007/s40262-022-01118-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。